NKGEN BIOTECH INC (NKGN)

US65488A1016 - Common Stock

0.64  +0.07 (+13.25%)

After market: 0.64 0 (0%)

Fundamental Rating

0

NKGN gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. NKGN has a bad profitability rating. Also its financial health evaluation is rather negative. NKGN is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

NKGN had negative earnings in the past year.
NKGN had a negative operating cash flow in the past year.

1.2 Ratios

NKGN has a worse Return On Assets (-503.34%) than 97.88% of its industry peers.
Industry RankSector Rank
ROA -503.34%
ROE N/A
ROIC N/A
ROA(3y)-167.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NKGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for NKGN has been increased compared to 1 year ago.
Compared to 1 year ago, NKGN has a worse debt to assets ratio.

2.2 Solvency

NKGN has an Altman-Z score of -22.30. This is a bad value and indicates that NKGN is not financially healthy and even has some risk of bankruptcy.
NKGN has a worse Altman-Z score (-22.30) than 87.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.3
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

NKGN has a Current Ratio of 0.05. This is a bad value and indicates that NKGN is not financially healthy enough and could expect problems in meeting its short term obligations.
NKGN has a Current ratio of 0.05. This is amonst the worse of the industry: NKGN underperforms 99.47% of its industry peers.
NKGN has a Quick Ratio of 0.05. This is a bad value and indicates that NKGN is not financially healthy enough and could expect problems in meeting its short term obligations.
NKGN's Quick ratio of 0.05 is on the low side compared to the rest of the industry. NKGN is outperformed by 99.47% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05

More info and screens

0

3. Growth

3.1 Past

NKGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22816.70%.
EPS 1Y (TTM)-22816.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-839.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKGN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NKGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NKGEN BIOTECH INC

NASDAQ:NKGN (12/20/2024, 8:00:01 PM)

After market: 0.64 0 (0%)

0.64

+0.07 (+13.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12
Earnings (Next)N/A N/A
Inst Owners10.03%
Inst Owner Change9.89%
Ins Owners0.58%
Ins Owner Change0%
Market Cap23.05M
AnalystsN/A
Price TargetN/A
Short Float %4.2%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.82
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS-1.63
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -503.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-167.1%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -22.3
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22816.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-839.29%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-985.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1301.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1297.96%
OCF growth 3YN/A
OCF growth 5YN/A